These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37151150)

  • 21. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.
    Ahsan S; Raabe EH; Haffner MC; Vaghasia A; Warren KE; Quezado M; Ballester LY; Nazarian J; Eberhart CG; Rodriguez FJ
    Acta Neuropathol Commun; 2014 Jun; 2():59. PubMed ID: 24894482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.
    Zhang X; Zhang Z
    Trends Cancer; 2019 Dec; 5(12):799-808. PubMed ID: 31813457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.
    Nonnenbroich LF; Bouchal SM; Millesi E; Rechberger JS; Khatua S; Daniels DJ
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
    Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
    Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
    Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
    Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
    Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma.
    Dahl NA; Danis E; Balakrishnan I; Wang D; Pierce A; Walker FM; Gilani A; Serkova NJ; Madhavan K; Fosmire S; Green AL; Foreman NK; Venkataraman S; Vibhakar R
    Cell Rep; 2020 Apr; 31(1):107485. PubMed ID: 32268092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
    Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
    Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
    Peterson ER; Sajjakulnukit P; Scott AJ; Heaslip C; Andren A; Wilder-Romans K; Zhou W; Palavalasa S; Korimerla N; Lin A; O'Brien A; Kothari A; Zhao Z; Zhang L; Morgan MA; Venneti S; Koschmann C; Jabado N; Lyssiotis CA; Castro MG; Wahl DR
    Cancer Metab; 2024 Apr; 12(1):11. PubMed ID: 38594734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
    Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
    Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone H3K27M Mutation in Brain Tumors.
    El-Hashash AHK
    Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy for diffuse intrinsic pontine glioma: an update.
    Lu VM; Power EA; Zhang L; Daniels DJ
    J Neurosurg Pediatr; 2019 Nov; 24(5):593-600. PubMed ID: 31491754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
    Groves A; Cooney TM
    Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
    Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.